Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs 10X Genomics Inc (TXG) Price & Performance

MSTU is trading at $1.98, up 6.45% today, but faces significant headwinds with a bearish technical outlook and concerning fundamental metrics. The leveraged ETF structure has resulted in substantial losses, with reports indicating a 98% decline from November 2024 levels. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while key financial ratios remain unavailable for analysis.

The outlook remains challenging due to the ETF's leveraged structure and volatility decay. Investment opportunities are limited given the historical performance, while risks include continued erosion of value from daily rebalancing and dependence on MicroStrategy's underlying performance. The fund's viability remains in question based on recent performance trends.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.